Company profile
BIOVIE INC.
NASDAQ:BIVIBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Bezisterim | phase3 | — | 4 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04669028 | phase3 | completed | 2021-08-05 | 2023-09-30 | BioVie Inc. | A Phase 3 Study of NE3107 in Probable Alzheimer's Disease |
| NCT04112199 | phase2 | terminated | 2021-06-17 | 2023-05-08 | BioVie Inc. | A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites |
| NCT06757010 | phase2 | completed | 2025-03-26 | 2026-05-01 | BioVie Inc. | A Study of NE3107 in Early Parkinson's |
| NCT03107091 | phase2 | completed | 2017-07-15 | 2019-04-01 | BioVie Inc. | Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites |
| NCT05083260 | phase1_2 | completed | 2022-01-04 | 2022-11-21 | BioVie Inc. | NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa |
FDA applications (0)
No records yet.